Xoma Gets A Boost
Biopharmaceutical company Xoma (XOMA) is having its luck day. After its stock traded down as low as $2.24, its shares are up almost 20% today on news that it bacterial cell expression technology to Pfizer to Pfzier (PFE). The deal…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Biopharmaceutical company Xoma (XOMA) is having its luck day. After its stock traded down as low as $2.24, its shares are up almost 20% today on news that it bacterial cell expression technology to Pfizer to Pfzier (PFE). The deal comes with a $30 million up-front payment.
While that may not seem like much, XOMA lost $7.5 million on revenue of $14.1 million in the last quarter.
The stock still appears expensive, with a market cap of $370 million.
Maybe the royalties on the Pfizer deal, if there end up being any, will help justify the company’s valuation.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.
